372948-28-2

RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways.

RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model[1][2][3].

[1] Rausch M, et al. Recent considerations in the application of RAPTA‐C for cancer treatment and perspectives for its combination with immunotherapies[J]. Advanced Therapeutics, 2019, 2(9): 1900042.
[2] Weiss A, et al. In vivo anti-tumor activity of the organometallic ruthenium (II)-arene complex [Ru (η 6-p-cymene) Cl 2 (pta)](RAPTA-C) in human ovarian and colorectal carcinomas[J]. Chemical Science, 2014, 5(12): 4742-4748.
[3] Chatterjee S, et al. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem. 2008 Sep;13(7):1149-55. DOI:10.1007/s00775-008-0400-9